Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
  • C07J71/0005—Oxygen-containing hetero ring

Definitions

• This invention relates to a method for the preparation of sterile aqueous suspensions of ciclesonide by sterilization with moist heat.
• the invention further relates to pharmaceutical compositions in particular to aqueous suspensions of ciclesonide for administration by nebulization in the prophylaxis and/or treatment of respiratory diseases.
• U.S. Pat. No. 5,482,934 discloses pregna-1,4-diene-3,20-dione-16-17-acetal-21 esters and their use in the treatment of inflammatory conditions.
• the compounds have the general structure: wherein R1 is 2-propyl, 1-butyl, 2-butyl, cyclohexyl or phenyl; and R2 is acetyl or isobutanoyl.
• Ciclesonide is the INN for a compound of formula I in which R1 is cyclohexyl and R2 is isobutanoyl with the chemical name [11 ⁇ ,16 ⁇ (R)]-16,17[(Cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-dien-3,20-dion.
• Ciclesonide is only moderately absorbed after oral administration and has low systemic activity. Concentration of the drug in the lungs is high and metabolism by liver oxidases is very high, giving the drug a low plasma half-life. Systemic activity of ciclesonide is three times lower than that of budesonide, but anti-inflammatory activity is higher for the former.
• MDIs pressurized metered dose inhalers
• Suitable formulations for pressurized metered dose inhalers (MDIs) for inhalation for ciclesonide are for example disclosed in U.S. Pat. No. 6,264,923 and U.S. Pat. No. 6,120,752.
• nebulizers represent another class of devices allowing inhalative drug administration. Especially in case of children and elderly being not able to handle DPIs and MDIs correctly, nebulization is the preferred way of drug administration to the lungs. Thus it is desirable to provide ciclesonide in formulations suitable for administration by nebulization. Whereas in case of water-soluble drugs aqueous solutions are nebulized, this is not possible in case of water-insoluble drugs such as ciclesonide. Consequently these drug substances have to be applied in the form of suspensions.
• DPIs dry powder inhalers
• MDIs pressurized metered dose inhalers
• the particle size of the aerosol droplets after nebulization needs to be in the range of approximately 1-7 ⁇ m. If suspensions will be administered, the particle size of the suspended drug particles is critical, since only particles being smaller than the aerosol droplets themselves are nebulized. For example micronized drug substance with a mean particle size of 2-6 ⁇ m is suitable for such suspensions.
• suspensions for nebulization have to be isoosmotic in order to avoid irritation of the tissue coming into contact with the formulation.
• formulations for administration by nebulization have to be sterile. Whereas in case of solutions this can be achieved by sterilization of the final formulation by moist heat or by filtration through a bacteria retentive filter, achieving sterile suspensions with a defined particle size is more difficult. Sterilization by filtration is no option when micronized drug substance with a mean particle size of 2-6 ⁇ m is used, since the particles are not able to pass the filter.
• WO99/25359 describes a process for the sterilization of a powdered form of a gluco corticosteroid.
• WO99/25359 discloses that the sterilization process of glucocorticosteroids by dry heat can be carried out at a significantly lower temperature than that considered necessary for the heat sterilization of other substances. The drug substance is exposed to 110-120° C. for no longer than 10 h.
• WO99/25359 further discloses sterile pharmaceutical formulations comprising a glucocorticosteroid and one or more pharmaceutically acceptable additives, diluents or carriers.
• additives include surfactants, pH regulating agents, chelating agents, agents rendering the suspension isoosmotic and thickening agents.
• These sterile formulations can be produced by mixing the sterilized glucocorticosteroid with any suitable additional ingredients, e.g. a surfactant, pH regulating or chelating agent, an agent rendering the suspension isoosmotic or a thickening agent. All components other than the glucocorticosteroid, can be produced by sterile filtration of their aqueous solutions. Examples 4 and 5 are related to sterile formulations comprising budesonide.
• WO00/25746 discloses a process for preparing a sterile micronised glucocorticosteroid (beclomethasone dipropionate) by gamma-irradiation.
• Another method for providing sterile aqueous pharmaceutical compositions is sterilization of the suspension by radiation.
• Ilium et al (Pharm. Chemi. Sci., Ed. 2, 1974, pp. 167-174) recommend a sterilization process for steroid-containing aqueous suspension by beta ray or gamma ray irradiation.
• WO 04/004739 is related to a ciclesonide-containing sterile aqueous suspension sterilized by autoclaving, wherein the concentration of ciclesonide after autoclaving is 95% or more comparing to that before autoclaving. It is further disclosed that it has been found that the uniformity of ciclesonide content can be maintained when hydroxypropylmethylcellulose is present in the suspension, even after sterilization by autoclaving.
• PulmicortTM and FlixotideTM Commercially available suspension formulations for glucocorticosteroids for nebulization are e.g. available under the tradenames PulmicortTM and FlixotideTM.
• PulmicortTM nebules contain budesonide as drug substance.
• the suspension is composed of sodium chloride (agent to adjust osmolality) polysorbate 80 (suspending agent), sodium EDTA (chelating agent) citric acid/sodium citrate (buffering agent) and water.
• FlixotideTM nebules contain fluticasone propionate.
• the suspension is composed of sodium chloride (agent to adjust osmolality), polysorbate 20 and sorbitan monolaurate (suspending agents), monosodium phosphate dihydrate and dibasic sodium phosphate anhydrous (buffering agent) and water.
• sodium chloride agent to adjust osmolality
• polysorbate 20 and sorbitan monolaurate suspending agents
• monosodium phosphate dihydrate and dibasic sodium phosphate anhydrous buffering agent
• sterile aqueous suspensions of ciclesonide comprising agents for adjusting osmolality can be prepared by autoclaving aqueous suspension of ciclesonide when using non-ionic agents for adjusting the osmolality as excipients in the suspension. No clogging of ciclesonide particles and no significant increase of the particle size of ciclesonide during the sterilization process is observed.
• Subject of the present invention is therefore a method for preparing a sterile aqueous suspension of ciclesonide suitable for nebulization comprising the steps of:
• Ciclesonide is the INN for an active compound having the chemical name [11 ⁇ ,16 ⁇ -(R)]-16,17-[(cyclohexylmethylene)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione. Ciclesonide and its preparation are described in U.S. Pat. No. 5,482,934. According to the invention, the name ciclesonide also includes solvates of ciclesonide, physiologically functional derivatives of ciclesonide or solvates thereof.
• the 21-hydroxy compound has the chemical name 16 ⁇ ,17-(22R,S)-cyclohexylmethylenedioxy-11 ⁇ ,21-dihydroxy-pregna-1,4-diene-3,20-dione. This compound and its preparation are disclosed in WO 94/22899.
• the name “ciclesonide” is understood as meaning not only the pure R epimer of the compound [11 ⁇ ,16 ⁇ ]16,17-[(cyclohexylmethylene)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione but also R/S epimer mixtures in any desired mixing ratio (that is the compounds [11 ⁇ ,16 ⁇ (R)]-16,17-[(cyclohexylmethylene)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy) pregna-1,4diene3,20-dione and [11 ⁇ ,16 ⁇ (S)]-16,17-[(cyclohexylmethylene)bis(oxy)]-11-hydroxy-21-(2-methyl1-oxopropoxy)pregna-1,4-diene-3,20-dione), those being preferred which essentially consist of R epimers.
• essentially consisting of R epimers means that the proportion
• the mean particle size of ciclesonide present in the aqueous suspension is preferably within a range, which allows effective administration of ciclesonide by nebulisalion.
• the mean particle size of ciclesonide (as determined by laser diffraction) is less than 12 ⁇ m, preferably from 0.1 to 8 ⁇ m, preferably 1 to 6 ⁇ m, particularly preferably 2 to 4 ⁇ m
• Ciclesonide with such particle size can be obtained by micronization of ciclesonide particles with greater particle size obtained in the manufacturing process of ciclesonide (e.g. as described in WO98/009982) or directly by crystallization processes leading to the desired mean particle size.
• the amount of ciclesonide, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof which is required to achieve a therapeutic effect will, of course, vary with the subject under treatment, and the particular disorder or disease being treated. It will further depend on the efficiency of the nebulizer used and the deposition of the aerosol droplets in the lung. Suitable concentrations of ciclesonide within the suspension for nebulization can be in the range of 0.005% to 0.5% (w/v) (i.e. 0.05 mg/ml to 5 mg/ml).
• Non-ionic agent for adjusting the osmolality in connection with the invention refers to pharmaceutically acceptable agent, which is of non-ionic nature and which is customarily used to render the Pharmaceutical solutions and/or suspensions isoosmotic with body fluids.
• examples for non-ionic agents for adjusting the osmolality which can be used in connection with the present invention, are selected from the group of mannitol, glycerol, glucose, lactose, trehalose, sucrose, propylene glycol, sorbitol, xylitol, polyethylene glycol, ethanol, isopropanol, cyclodextrins, derivatives of cyclodextrines and mixtures thereof.
• Preferred examples are mannitol, glycerol, glucose or mixtures thereof.
• the aim of adding an agent for adjusting the osmolatity is to provide a suspension according to the invention, which is isoosmotic or close to isoosmotic with body fluids, namely 290 mosmol/kg.
• the non-ionic agent for adjusting osmolality is present in such an amount in the suspension according to the invention to provide an osmolality of the suspension in the range of 225-430 mosmol/kg, preferably in the range of 250 to 350 mosmol/kg, particularly preferably in the range of 280 to 300 mosmol/kg.
• the amount of agents needed to adjust the osmolality will depend on the presence of other excipients within the formulation contributing to the overall osmolality of the formulation.
• the suspension used in the process according to the invention may contain one ore more additional suitable excipients.
• Suitable excipients include suspending agents, agents for modifying the pH of the suspension, chelating agents and optionally preservatives.
• ionic excipients e.g. ionic buffer systems
• suitable excipients are selected from the group of non-ionic excipients.
• Suspending agents are used to obtain a uniform distribution of single particles of ciclesonide within the formulation resulting in a homogenous suspension.
• suspending agents include polyoxyethylene sorbitan fatty acid esters (polysorbates), alkyl aryl polyether alcohols such as tyloxapol, poloxamers, poloxamines, polyoxyethylene castor oil derivatives, phospholipids, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, polyvinylalcohol and mixtures thereof.
• concentrations of the suspending agents used within the formulation are largely depended on the concentration of the suspended drug substance.
• the suspending agent is added in an amount to achieve effective suspension of ciclesonide to provide a homogeneous suspension.
• the ratio between drug substance and suspending agent can usually vary from 0.05 to 50.
• agents for modifying the pH of the suspension can be added. Suitable examples, which may be mentioned are for example inorganic and organic acids selected from the group of hydrochloric acid, phosphoric acid, sulphuric acid, citric acid, tartaric acid, lactic acid and mixtures thereof. Preferably organic acids are present.
• organic acids are present.
• ciclesonide is known to be unstable under alkaline conditions the pH-value of the suspension should preferably be adjusted to yield neutral or slightly acidic conditions.
• Chelating agents such as editic acid or edetate salts can be added in suitable concentrations (e.g. 0.01-0.1%). They can serve as antioxidant synergists by sequestering the traces of heavy metals thereby improving the chemical stability of the drug substance or of the excipients. In addition, they have some antimicrobial activity.
• the formulation according to the invention might contain one or more preservatives although made sterile by the process according to the present invention. It is preferred to have a preservative present in the formulations according to the invention in order to preserve the microbiological quality during use. This is especially important in case of multiple dose vials.
• Suitable preservatives for example are benzoic acid, sorbic acids and its salts, propionic acid and its salts, phenol and derivatives such as cresol and chlorocresol, chlorobutanol, benzyl alcohol, phenyl ethyl alcohol, butyl paraben and propyl paraben.
• Preferred formulations according to the invention contain the following components suspended/dissolved in water for injections: Ciclesonide micronized 0.025-0.1% (w/v) Glycerol 2.5% (w/v) Polysorbate 20 0.0125-0.05% (w/v) Ciclesonide micronized 0.025-0.1% (w/v) Glycerol 2.5% (w/v) Polysorbate 80 0.0125-0.05% (w/v) Ciclesonide micronized 0.025-0.1% (w/v) Mannitol 5.0% (w/v) Polysorbate 20 0.0125-0.05% (w/v) Ciclesonide micronized 0.025-0.1% (w/v) Mannitol 5.0% (w/v) Polysorbate 80 0.0125-0.05% (w/v)
• the present invention relates to a sterile aqueous suspension of ciclesonide suitable for nebulization containing one or more pharmaceutically acceptable excipients, which one or more excipients are all non-ionic excipients.
• the invention also relates to a sterile aqueous suspension of ciclesonide, containing at least one non-ionic agent to adjust the osmolality and optionally further pharmaceutically acceptable excipients.
• the sterile aqueous suspension is obtainable by a method of preparation according to the present invention.
• the sterile aqueous suspension does not contain a preservative.
• the invention in another aspect relates to an aqueous suspension of ciclesonide for administration by nebulization, wherein the concentration of ciclesonide within the suspension for nebulization is in the range of 0.005% to 0.5% (w/v) (i.e. 0.05 mg/ml to 5 mg/ml).
• the suspension is a sterile suspension.
• Suspensions used in the process according to the invention can be prepared by conventional methods for the preparation of suspension formulations.
• the suspensions used in the process according to the invention can be prepared by dissolving the non-ionic agent for adjusting the osmolality and optionally other excipients (e.g. suspension agent) in purified water or water for injections. If desired, this solution of excipients can be filtered (sterile filtration).
• Ciclesonide with a suitable particle size is homogenously suspended within the solution (e.g. by stirring or by employing a turboemulslfier, eg Ultraturrax).
• the final formulation is filled into suitable containers (e.g. vials), sealed and sterilized by moist heat.
• the formulation can be sterilized by moist heat as bulk and afterwards filled into sterile vials under aseptic conditions and sealed.
• glass vials containers prepared by a form-fill-seal process are also suitable.
• the formulation can be sterilized by moist heat as bulk and filled under aseptic conditions afterwards. Filling into form-fill-seal containers and terminal sterilization by moist heat is also possible.
• Sterilization by moist heat or autoclaving in connection with the present invention refers to a method of sterilizing in a suitable autoclaving equipment by steam with high pressure and temperature which meets the criteria according to US Pharmacopoeia 26, chapter 1211 “Sterilization and sterility assurance of compendial articles”, European Pharmacopeia (Ph. Eur. 4.07, chapter 5.1.1. “Methods of preparation of sterile products”), or other Pharmacopoelas.
• Sterile aqueous suspension in this context refers to an aqueous suspension which meets the criteria according to US Pharmacopoeia 26 chapter 71 “Sterility tests”, European Pharmacopeia (Ph. Eur. 4.07 chapter 2.6.1. “Sterility” . . . ), or other Pharmacopoeias.
• the formulation according to the invention is exposed to a temperature above 90° C., preferably 120° C., particularly preferably of at least 121° C.
• the formulation according to the invention is exposed to a temperature of at least 121° C. for at least 15 min in the presence of saturated steam under pressure.
• Other suitable combinations of temperatures (e.g. temperatures below 90° C.) and time may be used as well as long as they lead to a sterile formulation as required by the standards set in the various pharmacopoeias.
• 5.5 kg of glucose and 12.5 g of Tyloxapol are dissolved in 100 liters of water for injections.
• the solution has been filtered through a filter with a pore size of 0.2 ⁇ m.
• 25 g of micronized ciclesonide is added and the suspension is stirred for at least 1 hour in order to yield a homogenous suspension.
• the suspension is filled into glass bottles containing each about 1 liter.
• the bottles are sterilized within an autoclave at a temperature of 121° C. for 20 min in the presence of saturated steam. After the sterilization process the sterile suspension is filled in a form-fill-seal process under aseptic conditions.
• the final product is composed of 2 ml of the suspension in a form-fill-seal container made from polyethylene or polypropylene.
• Suspensions containing 0.05% of micronized ciclesonide, 0.025% of Polysorbate 20 (Formulation I), Polysorbate 80 (Formulation II) or Cremophor RH40 (Formulation II) as suspending agents and 0.9% of sodium chloride as agent for adjusting the osmolality in water for injections have been prepared.
• the suspensions have been filled into glass vials and have been sterilized by moist heat (121° C., 20 min). Prior to the sterilization and afterwards the size of the suspended particles has been measured by laser diffraction (Particle sizer series 2600, Malvern, suspension diluted with Polysorbate 80 solution 0.1% in water, calculation according to Fraunhofer, ultrasound applied if necessary).
• d10, d50 and d90 values are presented in the table below.
• d10, d50 and d90 values in connection with this invention mean, that for 10, 50 or 90% of the total volume of particles the size is lower.
• Prior to the measurements the samples were shaken in order to resuspend sedimented particles.
• Prior to sterilization Formulation d10 [ ⁇ m] d50 [ ⁇ m] d90 [ ⁇ m] d10 [ ⁇ m] d50 [ ⁇ m] d90 [ ⁇ m] I 1.98 4.15 8.83 13.53 80.06 110.12 II 2.27 4.74 9.32 11.39 79.01 109.92 III 2.05 4.29 8.81 10.37 74.05 108.88
• Suspensions containing 0.05% of micronized ciclesonide, 0.025% of Polysorbate 20 as suspending agent and 2.5% of glycerol (Formulation IV), 5% of mannitol (Formulation V) or 5% of glucose (Formulation VI) as agent for adjusting the osmolality in water for injections have been prepared.
• the suspensions have been filled into glass vials and have been sterilized by moist heat (121° C., 20 min). Prior to the sterilization and afterwards the size of the suspended particles has been measured by laser diffraction (Mastersizer 2000, Malvern, suspension diluted with water, calculation according to Mie, assumed refractive index of suspended particles 1.52).
• d10, d50 and d90 values are presented in the table below. Prior to sterilization After sterilization Formulation d10 [ ⁇ m] d50 [ ⁇ m] d90 [ ⁇ m] d10 [ ⁇ m] d50 [ ⁇ m] d90 [ ⁇ m] IV 0.432 2.357 4.854 1.260 2.317 3.980 V 0.447 2.260 4.638 1.248 2.281 3.871 VI 0.461 2.424 4.943 1.268 2.713 6.036
• Suspensions containing 0.05% of micronized ciclesonide, 0.025% of Polysorbate 20 as suspending agent and 0.9% of sodium chloride (Formulation I) as ionic agent for adjusting the osmolality or no ionic agent at all (Formulation VII) have been prepared.
• the suspensions have been filled into glass vials and have been sterilized by moist heat (121° C., 20 min). Prior to the sterilization and afterwards the size of the suspended particles has been measured by laser diffraction (Mastersizer 2000, Malvern, suspension diluted with water, calculation according to Mie, assumed refractive index of suspended particles 1.52). Before the measurements the samples were shaken in order to resuspend sedimented particles.
• d10, d50 and d90 values are presented in the table below. Prior to sterilization After sterilization Formulation d10 [ ⁇ m] d50 [ ⁇ m] d90 [ ⁇ m] d10 [ ⁇ m] d50 [urn] d90 [ ⁇ m] I 0.382 2.581 5.623 Large white agglomerates VII 0.393 2.508 5.483 1.259 2.268 3.887
• the suspension containing no ionic agent for adjusting the osmolality did not show any significant increase of the particle size after the sterilization process.
• Ciclesonide suspensions containing 0.05% of micronized ciclesonide have been prepared by the method described in example 1 and 2.
• citric acid has been added to adjust be pH of the suspension.
• the particle size of the samples Prior to and after sterilization the particle size of the samples has been measured by the method described in example 6.
• Ciclesonide suspensions containing 0.05% of micronized ciclesonide have been prepared by the method described in example 5 and 6.
• citric acid buffers pH5 citric acid/sodium citrate
• pH5 citric acid/sodium citrate
• the measured particle sizes prior and after sterilization indicate that with increasing buffer concentration the particle size after sterilization increases. This shows that the suspensions containing ionic buffering agents are susceptible to particle growth during the sterilization process.
• Suspensions containing 0.05% of micronized ciclesonide, 0.025% of Polysorbate 20 as suspending agent and 2.5% of glycerol (Formulation IV) or 5% of mannitol (Formulation V) as agent for adjusting the osmolality in water for injections have been prepared.
• the suspensions have been filled into glass via's and have been sterilized by moist heat at 110° C. for 120 min. Prior to and after sterilization the particle size of the samples has been measured by the method described in example 6. After approx.
• the aqueous suspension of ciclesonide according to the invention can be used for the prophylaxis or treatment of a clinical condition in a mammal, such as a human (also referred to as patient), for which a glucocorticosteroid is indicated.
• a mammal such as a human (also referred to as patient)
• the present invention provides a method for the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which a glucocorticosteroid is indicated, which comprises administration of a therapeutically effective amount of an aqueous suspension of ciclesonide, in particular a sterile aqueous suspension of ciclesonide according to the invention.
• the aqueous suspension of ciclesonide according to the invention is particularly suitable in the prophylaxis and/or treatment of respiratory diseases.
• Respiratory disease according to the invention includes in particular diseases associated with inflammatory airway diseases and/or reversible airways obstruction such as asthma, nocturnal asthma, exercise-induced asthma, chronic obstructive pulmonary diseases (COPD) (e.g. chronic and whez bronchitis, emphysema), croup, respiratory tract infection and upper respiratory tract disease (e.g. rhinitis, such as allergic and seasonal rhinitis).
• COPD chronic obstructive pulmonary diseases
• croup respiratory tract infection and upper respiratory tract disease
• rhinitis such as allergic and seasonal rhinitis
• aqueous suspensions according to the invention are particularly suitable for intrapulmonal administration in particular through administration by nebulization.
• the suspension may also be administered by any other suitable route.
• nebulizers Pani LC starTM, Pan LC plusTM, Omron VCTM, Sidestream MS 2400 and 2200TM, HaloliteTM, CirismeTM and compressors: eg Pari PronebTM Ultra, DeVilbriss Pulmo AideTM, Medic Aid PortanebTM Invacare EnvoyTM, MPV Truma MicroDropTM) and new generation nebulizers with different operation principles (e.g. eflowTM by PARI, Omron U22 and MicroairTM by Omron, AeroNebTM by Aerogen, TouchsprayTM by Odem, MicrohalerTM by Pfeiffer).
• the patient in connection with the invention is a child.
• Child in connection with the invention refers to a human below eighteen years (e.g. seventeen years, fifteen years, ten years, nine years, five years, two years, 6 months etc.).
• child refers to a pre-pubertal human, and in particular to a human from 6 months to 10 years of age, in particular 12 months to 8 years of age.
• ciclesonide or a pharmaceutical acceptable salt, solvate or physiologically functional de rivative thereof which is required to achieve a therapeutic effect will, of course, vary with the patient under treatment, and the particular disorder or disease being treated.
• ciclesonide is generally administered to patients by inhalation at a daily dose of from 0,05 mg to 2 mg, preferably 0.1 to 1 mg, which can be administered in one or several doses.
• the dose is preferably a daily dose and administered once or twice daily, preferably once daily.
• a once daily dose may be administered any time of the day, e.g. in the morning or preferably in the evening.
• the administration of a daily dose of ciclesonide is preferably part of a continuous treatment regimen, preferably a treatment period of more than one day, particularly preferably more than one week, e.g. a two week treatment period, a one month treatment period, a one year treatment period or a life long treatment period.
• the dosage of each administration can be the same or varied throughout the continuous treatment regimen.
• a drug product comprising a sealed container containing an aqueous suspension according to the invention and a label indicating administration by nebulization in a continuous treatment regimen.
• the container can be of any suitable kind, e.g. a form-fill-seal container made from polyethylene or polypropylene.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pulmonology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Dispersion Chemistry (AREA)
• Otolaryngology (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Steroid Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=34684543

Family Applications (2)

Family Applications After (1)

Country Status (21)

Cited By (14)

Families Citing this family (8)

Citations (25)

Family Cites Families (24)

• 2004
  • 2004-12-10 PE PE2004001247A patent/PE20050941A1/es active IP Right Grant
  • 2004-12-14 MY MYPI20045134A patent/MY159377A/en unknown
  • 2004-12-15 KR KR1020067013760A patent/KR101086095B1/ko not_active Expired - Lifetime
  • 2004-12-15 AU AU2004298447A patent/AU2004298447B2/en not_active Expired
  • 2004-12-15 CA CA2549038A patent/CA2549038C/en not_active Expired - Fee Related
  • 2004-12-15 US US10/582,499 patent/US20070117783A1/en not_active Abandoned
  • 2004-12-15 EA EA200601091A patent/EA012388B1/ru not_active IP Right Cessation
  • 2004-12-15 BR BRPI0416854A patent/BRPI0416854B8/pt active IP Right Grant
  • 2004-12-15 UA UAA200607589A patent/UA87123C2/uk unknown
  • 2004-12-15 EP EP04804847A patent/EP1697398B1/en not_active Expired - Lifetime
  • 2004-12-15 NZ NZ547217A patent/NZ547217A/en not_active IP Right Cessation
  • 2004-12-15 JP JP2006544438A patent/JP5001657B2/ja not_active Expired - Lifetime
  • 2004-12-15 AR ARP040104661A patent/AR046892A1/es not_active Application Discontinuation
  • 2004-12-15 CN CNB2004800368287A patent/CN100513417C/zh not_active Expired - Lifetime
  • 2004-12-15 WO PCT/EP2004/053495 patent/WO2005058935A2/en not_active Ceased
  • 2004-12-15 EP EP10173237.8A patent/EP2319858B1/en not_active Expired - Lifetime
  • 2004-12-16 TW TW093139206A patent/TWI350757B/zh not_active IP Right Cessation
• 2006
  • 2006-05-07 IL IL175461A patent/IL175461A/en active IP Right Grant
  • 2006-05-11 ZA ZA200603768A patent/ZA200603768B/en unknown
  • 2006-06-05 EC EC2006006608A patent/ECSP066608A/es unknown
  • 2006-06-07 CO CO06054801A patent/CO5700832A2/es active IP Right Grant
  • 2006-06-30 NO NO20063047A patent/NO337225B1/no unknown
• 2015
  • 2015-09-25 US US14/865,637 patent/US11052042B2/en not_active Expired - Fee Related

Patent Citations (26)

Also Published As

Similar Documents

Legal Events